Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan in refractory/recurrent hepatoblastoma
NCT00287976Phase 2Unknown
- Sponsor
- Children's Cancer and Leukaemia Group
- Start
- Apr 2003
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in hepatoblastoma, sponsored by Children's Cancer and Leukaemia Group. Primary endpoints: Best overall response rate and Rate of early progression. Status: unknown.
02
Drugs
irinotecan
03
Conditions
hepatoblastoma
Beyond the preview
Go deeper on NCT00287976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00287976.